Sign in

AMEDISYS (AMED)

Amedisys, Inc. is a leading healthcare services company focused on providing high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population. The company operates through three main business segments: home health, hospice, and high acuity care, offering a range of services designed to help patients manage chronic diseases, recover and rehabilitate after operations or injuries, and maintain independence and quality of life at home.

  1. Home Health - Provides a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness, or need assistance with completing important tasks.
  2. Hospice - Offers palliative care and comfort to terminally ill patients and their families, focusing on support and dignity during their final days.
  3. High Acuity Care - Delivers essential elements of inpatient hospital, palliative, and skilled nursing facility care to patients in their homes.

You might also like

NamePositionExternal RolesShort Bio

Richard Ashworth

ExecutiveBoard

President and Chief Executive Officer

CEO of Amedisys, Inc. since April 10, 2023 , and has served as a board member since 2023. Previously, he held executive roles at Tivity Health and Walgreens.

View Report →

Scott G. Ginn

ExecutiveBoard

Chief Operating Officer

Board of Directors at Investar Holding Corporation

Scott G. Ginn has served as the Chief Operating Officer at Amedisys, Inc. since November 2022. He also serves as Executive Vice President (since February 2021) and Chief Financial Officer (since October 2017). Additionally, he has held progressive financial roles at Amedisys and serves on the board of directors of Investar Holding Corporation, and is a Certified Public Accountant.

Denise Bohnert

Executive

Chief Compliance Officer

Denise Bohnert is the Chief Compliance Officer at AMED since September 2019, responsible for managing and overseeing the compliance program. Previously, she served as Deputy Compliance Officer from January 2017 to August 31, 2019, demonstrating her strong background in regulatory compliance.

Jennifer Guckert Griffin

Executive

Chief Legal Officer

Jennifer Guckert Griffin is the Chief Legal Officer and Corporate Secretary at Amedisys, Inc. since November 2024 and 2016 respectively. She previously served as Interim Chief Legal Officer (September 2022–November 2024) and as Senior Vice President, Deputy General Counsel, and Corporate Secretary, having joined Amedisys in 2013.

Nick Muscato

Executive

Chief Strategy Officer

Nick Muscato has been the Chief Strategy Officer at AMED since April 2022, where he oversees investor relations, treasury, corporate strategy, data & analytics, managed care, and strategic investment functions. He joined AMED in March 2015 in a corporate strategy role and later assumed additional responsibilities in the Finance organization.

Bruce D. Perkins

Board

Board Member of Amedisys, Inc.

Managing Member, Perkins, Smith & Associates, L.L.C.; Managing Member, MMBP Holdings, LLC

Bruce D. Perkins is a seasoned healthcare veteran serving on the board of Amedisys, Inc. and leading the Compliance and Ethics Committee; he has over 45 years of industry experience and has held significant executive roles at other healthcare organizations.

Ivanetta Davis Samuels

Board

Director

Senior Vice President, General Counsel, and Corporate Secretary at Meharry Medical College

Ivanetta Davis Samuels has served as a director on Amedisys’ board since 2020. She contributes to key committees including the Nominating and Corporate Governance, Quality of Care, and Compliance and Ethics Committees, bringing over 25 years of legal and healthcare expertise.

Julie D. Klapstein

Board

Independent Lead Director

MultiPlan; Aptarro; HealthCare Information Management; Unislink; Omada Health; Revecore Technologies; NextGen Healthcare, Inc.; Oak Street Health

Currently serving as the Independent Lead Director at AMED since February 2022. She brings over 35 years of healthcare leadership experience, including her tenure as the founding CEO of Availity and executive roles at Phycom, Inc. and Sunquest Information Systems.

Molly J. Coye

Board

Chair, Nominating and Corporate Governance Committee

Headspace Health; Curai; SameSky Health; SFJAZZ

Molly J. Coye, MD, serves as Chair of the Nominating and Corporate Governance Committee at AMED and is a member of the Quality of Care and Compliance and Ethics Committees, demonstrating her strong corporate governance expertise.

Paul B. Kusserow

Board

Chairman of the Board

Executive Chairman of United Women's Health; Executive Chairman of Careforth; Co-Founder and Chairman of Healthpilot Technologies

Paul B. Kusserow has served as the Chairman of the Board at AMED since October 2019. He previously served as CEO from December 2014 to April 2022 and again from November 2022 to April 2023, and he brings over 20 years of experience in the healthcare industry.

Teresa L. Kline

Board

Member of the Board of Directors

SaVida Health; National Seating & Mobility, Inc.; Presbyterian Healthcare Services; Vice Chairman of the Board of Trustees of Kalamazoo College

Teresa L. Kline has served as a board member of Amedisys since 2019. She is active on key committees including the Audit, Compensation, and Nominating & Corporate Governance Committees.

Vickie L. Capps

Board

Director and Audit Committee Chair

Board of Directors and Audit Committee Chair at Janux Therapeutics ; Board of Directors at Enable Injections, Inc. ; Board of Directors at Breg, Inc. ; Senior Advisory Board Member at Consonance Capital Partners ; Board of Directors at San Diego State University Research Foundation

Vickie L. Capps has served as a board member and Audit Committee Chair at AMED since 2019, and is recognized as an audit committee financial expert with extensive experience as a former CFO and CPA. Her background spans active leadership roles across multiple healthcare companies.

Jeffrey A. Rideout

Chair, Quality of Care Committee

Jeffrey A. Rideout, MD, serves as the Chair of the Quality of Care Committee at AMED, where he helps oversee quality medical care and patient safety. He has extensive healthcare leadership experience from various roles in the industry.

  1. Regarding your home health 5% volume growth guidance, can you break down the expected contribution from Medicare Advantage versus fee‐for‐service and explain how you plan to mitigate the impact of historically declining fee‐for‐service volumes?
  2. With current labor constraints forcing reliance on NTUC and PRN staffing, what concrete measures beyond enhanced benefits are you implementing to reduce turnover, and how do you plan to avoid turning away patient volume?
  3. Considering Contessa’s persistent EBITDA drag of around $30 million, what is your detailed roadmap—including key milestones and timelines—to achieve breakeven or margin improvement in that segment?
  4. In light of your stated willingness to cancel contracts with partners offering unacceptable rates, can you elaborate on the criteria you use in assessing these opportunities and the expected impact on your revenue mix and clinical capacity utilization?
  5. With the rollout of the ConnectRN gig staffing model, what measurable improvements in clinical visit productivity have you seen in the pilot regions, and how do you plan to scale the model without compromising service quality or further driving up labor costs?

Research analysts who have asked questions during AMEDISYS earnings calls.

Andrew Mok

Barclays

4 questions for AMED

Also covers: ACHC, ADUS, AGL +21 more

Brian Tanquilut

Jefferies

4 questions for AMED

Also covers: ACHC, ADUS, AHCO +26 more

John Ransom

Raymond James

4 questions for AMED

Also covers: ACHC, ADUS, ALHC +11 more

Justin Bowers

Deutsche Bank AG

4 questions for AMED

Also covers: CON, CRL, CTLT +9 more

A.J. Rice

UBS Group AG

3 questions for AMED

Also covers: ACHC, AMN, BTSG +20 more

Joanna Gajuk

Bank of America

3 questions for AMED

Also covers: ACHC, ADUS, AGL +21 more

Sarah James

Cantor Fitzgerald

3 questions for AMED

Also covers: ACHC, CI, CNC +15 more

Scott Fidel

Stephens Inc.

3 questions for AMED

Also covers: ACHC, ADUS, ALHC +16 more

Tao Qiu

Macquarie Group

3 questions for AMED

Also covers: ADUS, BKD, ENSG +5 more

Benjamin Mayo

Leerink Partners

2 questions for AMED

Also covers: ACHC, AGL, ARDT +10 more

Matthew Larew

William Blair & Company

2 questions for AMED

Also covers: ATR, DNA, MASS +10 more

Matt Larew

William Blair & Co.

2 questions for AMED

Also covers: MRVI, MXCT, RGEN +5 more

Whit Mayo

Leerink Partners

2 questions for AMED

Also covers: ACHC, AHCO, ALHC +9 more

Albert Rice

UBS

1 question for AMED

Also covers: ACHC, AMN, BTSG +20 more

Ben Hendrix

RBC Capital Markets

1 question for AMED

Also covers: ACHC, ARDT, AVAH +14 more

Benjamin Hendrix

RBC Capital Markets

1 question for AMED

Also covers: ACHC, ADUS, AHCO +24 more

Benjamin Rossi

JPMorgan Chase & Co.

1 question for AMED

Also covers: ARDT, AVAH, CON +6 more

Bill Sutherland

The Benchmark Company LLC

1 question for AMED

Also covers: ATIP, BEAT, CCRN +5 more

Gary Taylor

Cowen and Company

1 question for AMED

Matthew Borsch

BMO Capital Markets

1 question for AMED

Michael Murray

RBC Capital Markets

1 question for AMED

Also covers: ADUS, AHCO, AVAH +7 more

Nabil Gutierrez

Bank of America

1 question for AMED

Program DetailsProgram 1
Approval DateFebruary 2, 2023
End Date/DurationDecember 31, 2023
Total Additional Amount$100 million
Remaining Authorization$0 (No shares were repurchased)
DetailsRepurchases were restricted due to the Merger Agreement, except for certain exceptions. Methods included open market purchases, privately negotiated transactions, and trading plans under Exchange Act Rule 10b5-1. Factors influencing repurchases included share price, trading volume, market conditions, and business needs.
CustomerRelationshipSegmentDetails

Medicare

Major payor for home health and hospice services.

All

Represents approximately 70% to 74% of net service revenue.

Notable M&A activity and strategic investments in the past 3 years.

CompanyYearDetails

Evolution Health LLC

2024

Deal involved restricted cash placements with funds held in escrow for indemnity and closing payments, with amounts of $12.4M, $12.5M, and $7.5M recorded at different dates and fully released by September 30, 2024.

Home health provider in West Virginia

2023

Acquisition completed on January 20, 2023 for a purchase price of $0.4M paid in cash, with recorded goodwill of $0.3M and an additional $0.1M in other intangibles related to a certificate of need.

AssistedCare Home Health

2022

Announced on February 23, 2022 and closed on April 1, 2022, this acquisition involved purchasing two home health locations for a total price of $25M—$22.2M in cash/borrowings and $2.5M placed in escrow—with $24M in goodwill and $0.7M in other intangible assets recorded.

AssistedCare of the Carolinas

2022

Completed on April 4, 2022 under a definitive agreement announced on February 23, 2022 for a purchase price of $25.0M, financed through a mix of cash and escrow arrangements, recording $24M in goodwill and $0.7M in intangible assets, and strategically expanding Amedisys’ North Carolina market presence.

High Acuity Care home health operations (partner transaction)

2022

Finalized on March 23, 2022, this partner transaction saw the company contribute cash while the partner contributed home health operations, resulting in recorded goodwill of $8.5M, $0.4M in other intangibles, a noncontrolling interest of $8.9M, and about $2M in additional revenue to the high acuity care segment.

Recent press releases and 8-K filings for AMED.

Amedisys Merger with UnitedHealth Settled by DOJ
·$AMED
M&A
Legal Proceedings
  • The U.S. Justice Department has reached a proposed settlement for UnitedHealth Group's $3.3 billion acquisition of Amedisys, requiring the divestiture of 164 home health and hospice locations across 19 states.
  • These divestitures represent approximately $528 million in annual revenue and are intended to preserve competition in outpatient healthcare services.
  • Amedisys is required to pay a $1.1 million civil penalty and provide antitrust compliance training due to false certification during the investigation.
  • The settlement introduces operational complexity and potential delays to the merger's completion, including provisions for additional divestitures if regulatory approvals are not secured.
Aug 7, 2025, 5:08 PM
Amedisys Reports Q2 2025 Results Amid UnitedHealth Merger
·$AMED
Earnings
M&A
  • Amedisys reported strong financial results for Q2 2025, with net service revenue increasing to $621.9 million, a 5.2% rise from the previous year, and adjusted earnings per share rising to $1.54.
  • Despite improved adjusted EBITDA of $80.8 million, net income fell to $28.1 million from $32.3 million year-over-year, primarily due to merger-related expenses totaling $26.3 million in Q2 2025.
  • The company is currently in the process of merging with UnitedHealth Group and consequently did not hold a quarterly earnings call.
  • Most analysts maintain a cautious 'hold' rating on Amedisys stock, partly due to its relatively high price-to-earnings ratio of about 19 times projected earnings.
Jul 29, 2025, 10:23 PM
Amedisys Updates Divestiture Plans and Merger Transaction
·$AMED
M&A
  • Amedisys announced agreements for the sale of select home health and hospice care centers to affiliates of BrightSpring Health Services, with consummation contingent on the merger with UnitedHealth Group.
  • The company also entered into a separate agreement to sell additional home health care centers to affiliates of The Pennant Group, also subject to merger-related conditions.
  • The merger, which positions Amedisys as a wholly owned subsidiary of UnitedHealth Group, remains subject to multiple closing conditions and regulatory requirements, with executive oversight confirmed by CEO Richard Ashworth’s signature on May 1, 2025.
May 1, 2025, 12:00 AM
Amedisys Inc Reports Q1 2025 Financial Results
·$AMED
Earnings
M&A
  • Net service revenue increased by $23.4 million to $594.8 million compared to Q1 2024, indicating robust top-line growth.
  • Net income attributable to the company rose significantly to $61.0 million from $14.4 million in the prior period, with a GAAP diluted EPS of $1.84.
  • Non-GAAP measures also improved with an adjusted EBITDA of $68.8 million and higher adjusted net income and EPS, reflecting strong operational performance.
  • The company noted it will not host a quarterly earnings call due to its pending merger with UnitedHealth Group, marking an important strategic development.
Apr 23, 2025, 12:00 AM
Amedisys Reports Q4 2024 Financial Results & Strategic Initiatives
·$AMED
Earnings
M&A
  • Q4 2024 Performance: Consolidated revenue of $598.1M, net loss of $20.4M (merger-related expenses and a $48.4M impairment charge) alongside adjusted EPS of $0.96 and adjusted EBITDA of $54.6M
  • Full-Year 2024 Metrics: Net service revenue reached $2,348.3M, with adjusted EBITDA of $245.8M and adjusted net income of $142.7M (adjusted EPS of $4.32)
  • Organic Growth: Home Health same store admissions up 8%, Hospice ADC rising 0.5%, and High Acuity Care admissions increased by 29%
  • Strategic Initiatives: Pending merger with UnitedHealth Group Inc., efforts to optimize staffing ratios, and strong liquidity with net debt of $75.7M and $511.2M in revolving credit
Feb 26, 2025, 12:00 AM